2.21
price up icon5.24%   0.11
after-market After Hours: 2.18 -0.03 -1.36%
loading
Akebia Therapeutics Inc stock is traded at $2.21, with a volume of 6.11M. It is up +5.24% in the last 24 hours and down -19.05% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$2.10
Open:
$2.11
24h Volume:
6.11M
Relative Volume:
1.56
Market Cap:
$585.97M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-7.8929
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
-27.06%
1M Performance:
-19.05%
6M Performance:
-8.30%
1Y Performance:
+33.13%
1-Day Range:
Value
$2.07
$2.23
1-Week Range:
Value
$2.065
$3.20
52-Week Range:
Value
$1.52
$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
Name
Akebia Therapeutics Inc
Name
Phone
617-871-2098
Name
Address
245 FIRST STREET, CAMBRIDGE, MA
Name
Employee
181
Name
Twitter
@akebiatx
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
AKBA's Discussions on Twitter

Compare AKBA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
2.21 556.80M 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
144.09 63.86B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.44 41.80B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.27 40.88B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.48 22.98B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
445.43 19.53B 3.08B 1.24B 1.07B 25.61

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-04-25 Resumed H.C. Wainwright Buy
Apr-28-25 Initiated Leerink Partners Outperform
Apr-01-25 Initiated Jefferies Buy
Nov-29-23 Resumed BTIG Research Buy
Aug-28-23 Upgrade H.C. Wainwright Neutral → Buy
May-31-23 Upgrade Piper Sandler Neutral → Overweight
Mar-31-22 Downgrade H.C. Wainwright Buy → Neutral
Mar-31-22 Downgrade Mizuho Buy → Neutral
Mar-31-22 Downgrade Needham Buy → Hold
Mar-31-22 Downgrade Piper Sandler Overweight → Neutral
Mar-08-21 Initiated Cantor Fitzgerald Overweight
Jan-29-21 Downgrade JP Morgan Neutral → Underweight
Nov-14-19 Reiterated Needham Buy
Aug-06-19 Reiterated H.C. Wainwright Buy
Jul-11-19 Reiterated H.C. Wainwright Buy
May-02-19 Initiated JP Morgan Overweight
Mar-20-19 Initiated Citigroup Neutral
Sep-07-18 Resumed Morgan Stanley Equal-Weight
Aug-10-18 Reiterated Needham Buy
Jun-06-18 Reiterated H.C. Wainwright Buy
Dec-19-17 Initiated Piper Jaffray Overweight
Dec-07-17 Initiated BTIG Research Buy
Sep-15-17 Initiated RBC Capital Mkts Sector Perform
Jul-10-17 Reiterated H.C. Wainwright Buy
Apr-27-17 Reiterated H.C. Wainwright Buy
Apr-27-17 Reiterated Needham Buy
Dec-27-16 Reiterated H.C. Wainwright Buy
Dec-20-16 Reiterated JMP Securities Mkt Outperform
Nov-15-16 Initiated Aegis Capital Buy
Sep-29-16 Initiated Brean Capital Buy
Mar-16-16 Reiterated Needham Buy
Jan-21-16 Initiated Credit Suisse Neutral
View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

pulisher
05:45 AM

Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 7.4%Here's Why - MarketBeat

05:45 AM
pulisher
08:31 AM

Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat

08:31 AM
pulisher
07:33 AM

Akebia plummets as it abandons Vafseo for non-dialysis patients - MSN

07:33 AM
pulisher
06:58 AM

Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail

06:58 AM
pulisher
06:23 AM

Is Akebia Therapeutics Inc. (AX9) stock undervalued at current priceQuarterly Market Summary & Verified Momentum Stock Alerts - newser.com

06:23 AM
pulisher
06:23 AM

How high can Akebia Therapeutics Inc. stock goWeekly Profit Analysis & Expert Curated Trade Setup Alerts - newser.com

06:23 AM
pulisher
05:31 AM

Akebia Therapeutics (AKBA) Expected to Announce Earnings on Thursday - MarketBeat

05:31 AM
pulisher
05:06 AM

Is this a good reentry point in Akebia Therapeutics Inc.2025 Support & Resistance & Fast Gaining Stock Reports - newser.com

05:06 AM
pulisher
04:58 AM

How Akebia Therapeutics Inc. stock reacts to job market dataJobs Report & Momentum Based Trading Signals - newser.com

04:58 AM
pulisher
04:33 AM

Is Akebia Therapeutics Inc. (AX9) stock attractive for growth fundsJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com

04:33 AM
pulisher
04:15 AM

How rising interest rates impact Akebia Therapeutics Inc. stockWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com

04:15 AM
pulisher
01:50 AM

Can Akebia Therapeutics Inc. stock sustain revenue growth2025 Buyback Activity & Consistent Profit Alerts - newser.com

01:50 AM
pulisher
01:21 AM

Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsJuly 2025 Technicals & Real-Time Volume Analysis Alerts - newser.com

01:21 AM
pulisher
Oct 30, 2025

Will Akebia Therapeutics Inc. stock attract more institutional investorsWeekly Trade Recap & Weekly Hot Stock Watchlists - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Is Akebia Therapeutics Inc. (AX9) stock attractive for dividend growthJuly 2025 News Drivers & Expert Verified Stock Movement Alerts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients - Yahoo Finance

Oct 30, 2025
pulisher
Oct 30, 2025

Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $5.00 at BTIG Research - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Akebia Therapeutics (NASDAQ:AKBA) Shares Gap DownHere's Why - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

How Akebia Therapeutics Inc. stock trades during market volatilityInsider Buying & Stepwise Trade Signal Guides - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Akebia Therapeutics (AKBA) Receives Revised Price Target from HC Wainwright & Co. | AKBA Stock News - GuruFocus

Oct 30, 2025
pulisher
Oct 30, 2025

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights - MarketScreener

Oct 30, 2025
pulisher
Oct 30, 2025

HC Wainwright & Co. Maintains Akebia Therapeutics (AKBA) Buy Recommendation - Nasdaq

Oct 30, 2025
pulisher
Oct 30, 2025

How strong dollar benefits Akebia Therapeutics Inc. (AX9) stock2025 Big Picture & Fast Gain Swing Alerts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics - TipRanks

Oct 30, 2025
pulisher
Oct 30, 2025

Akebia price target lowered to $6 from $8 at H.C. Wainwright - TipRanks

Oct 30, 2025
pulisher
Oct 30, 2025

Will Akebia Therapeutics Inc. stock benefit from sector rotationJuly 2025 Breakouts & High Yield Equity Trading Tips - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

Will Akebia Therapeutics Inc. (AX9) stock profit from AI boomTrade Risk Report & AI Based Buy and Sell Signals - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Health Care Down on Mixed EarningsHealth Care Roundup - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

BTIG Lowers Akebia Therapeutics (AKBA) Price Target by 50% | AKB - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Why Is Akebia Therapeutics Stock Plunging TodayAkebia Therapeutics (NASDAQ:AKBA) - Benzinga

Oct 29, 2025
pulisher
Oct 29, 2025

Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core (NASDAQ:AKBA) - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Market Implications - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

Akebia stock plunges as kidney drug expansion plans scrapped - The Business Journals

Oct 29, 2025
pulisher
Oct 29, 2025

Akebia scraps plan for Vafseo trial after discussions with FDA - Fierce Pharma

Oct 29, 2025
pulisher
Oct 29, 2025

Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion - Stocktwits

Oct 29, 2025
pulisher
Oct 29, 2025

Akebia stock tumbles after FDA meeting on vadadustat trial design By Investing.com - Investing.com Canada

Oct 29, 2025
pulisher
Oct 29, 2025

Akebia Abandons Non-Dialysis Trial For Vafseo On Likely Higher Costs - Citeline News & Insights

Oct 29, 2025
pulisher
Oct 29, 2025

Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

Oct 29, 2025
pulisher
Oct 29, 2025

Morning Market Movers: CMBM, LRN, VRNS, AKBA See Big Swings - RTTNews

Oct 29, 2025
pulisher
Oct 29, 2025

FDA setback prompts Akebia to give up on broader Vafseo label - The Pharma Letter

Oct 29, 2025
pulisher
Oct 29, 2025

Akebia Therapeutics Stock Up 14%, Buy Or Wait? - Trefis

Oct 29, 2025
pulisher
Oct 29, 2025

Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 29, 2025
pulisher
Oct 29, 2025

Will earnings trigger a reversal in Akebia Therapeutics Inc.July 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Why institutional investors increase stakes in Akebia Therapeutics Inc. (AX9) stockAnalyst Downgrade & Long Hold Capital Preservation Tips - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Analyzing Akebia Therapeutics Inc. with risk reward ratio chartsPortfolio Return Report & Community Trade Idea Sharing - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Comparing Akebia Therapeutics Inc. in custom built stock radarsExit Point & AI Driven Price Predictions - newser.com

Oct 29, 2025
pulisher
Oct 28, 2025

Is Halting Broad Vafseo Expansion Shifting the Investment Outlook for Akebia Therapeutics (AKBA)? - simplywall.st

Oct 28, 2025
pulisher
Oct 28, 2025

Akebia Therapeutics Stock Rallied 16%Have You Assessed the Risk - Trefis

Oct 28, 2025
pulisher
Oct 28, 2025

Akebia Therapeutics (AKBA) Halts Expansion Plans for Vafseo - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Akebia (AKBA) Adjusts Strategy Following FDA Meeting on Anemia T - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Earnings Beat: Will Akebia Therapeutics Inc. stock benefit from sector rotationMarket Performance Recap & Technical Pattern Alert System - Fundação Cultural do Pará

Oct 28, 2025

Akebia Therapeutics Inc Stock (AKBA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$45.46
price up icon 3.18%
$22.15
price down icon 1.86%
drug_manufacturers_specialty_generic RDY
$13.29
price down icon 1.19%
$10.36
price up icon 0.00%
$143.21
price up icon 3.75%
$445.43
price down icon 1.79%
Cap:     |  Volume (24h):